GoodRx (NASDAQ: GDRX) director receives 4,642 deferred stock units
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Bruehlman Ronald E reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Ronald E. Bruehlman received a grant of 4,642 deferred stock units, each representing a contingent right to one share of Class A common stock, at no cash cost. The units vest 2% on May 31, 2026, with the remaining 98% vesting in substantially equal monthly installments over the following seven months, subject to continued service. The deferred stock units will settle upon the earliest of several events, including December 31, 2031 or separation from service. Following this grant, Bruehlman directly holds 133,918 Class A shares, including this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bruehlman Ronald E
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 4,642 | $0.00 | -- |
Holdings After Transaction:
Class A Common Stock — 133,918 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Deferred stock units granted: 4,642 units
Shares after transaction: 133,918 shares
Grant price: $0.0000 per unit
+3 more
6 metrics
Deferred stock units granted
4,642 units
Equity award of deferred stock units to director
Shares after transaction
133,918 shares
Total Class A shares directly held after grant
Grant price
$0.0000 per unit
Reported price for deferred stock unit grant
Initial vesting tranche
2% on May 31, 2026
First vesting portion of deferred stock units
Remaining vesting
98% over 7 months
Substantially equal monthly vesting after initial tranche
Latest settlement date
December 31, 2031
Latest possible settlement date for deferred units
Key Terms
deferred stock units, Separation from Service, Change in Control, Disability, +1 more
5 terms
deferred stock units financial
"Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock."
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Separation from Service financial
"The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2031; (ii) Separation from Service; (iii) a Change in Control;"
Change in Control financial
"The deferred stock units will settle on the earliest to occur of the following events ... (iii) a Change in Control; (iv) death; or (v) Disability"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Disability financial
"The deferred stock units will settle on the earliest to occur of ... (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc."
Deferred Compensation Plan for Directors financial
"Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors)."
A deferred compensation plan for directors is an arrangement that lets board members postpone receiving part of their pay until a later date—often retirement or a set future time—so the money can grow or be paid under specified conditions. Think of it like directing a portion of your paycheck into a locked savings account that pays out later; investors care because it creates future cash or stock obligations, signals how the company motivates and retains leadership, and can affect shareholder value through timing of payouts or potential dilution.
FAQ
What insider transaction did GoodRx (GDRX) report for Ronald E. Bruehlman?
GoodRx reported a grant of 4,642 deferred stock units to director Ronald E. Bruehlman. These units are equity compensation, not an open-market purchase, and each unit represents a contingent right to receive one share of Class A common stock at settlement.
How do the 4,642 deferred stock units for GoodRx (GDRX) vest?
The 4,642 deferred stock units vest 2% on May 31, 2026, with the remaining 98% vesting in substantially equal monthly installments over the next seven months. Vesting is conditioned on Bruehlman’s continued service through each applicable vesting date.
When will Ronald E. Bruehlman’s GoodRx (GDRX) deferred stock units settle?
The deferred stock units will settle in shares on the earliest of several events: December 31, 2031, separation from service, a change in control, death, or disability, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors.